These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 34991104)
1. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. Watson TR; Gao X; Reynolds KL; Kong CY JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401 [TBL] [Abstract][Full Text] [Related]
3. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis. Wan X; Zhang Y; Tan C; Zeng X; Peng L JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633 [TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113 [TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066 [TBL] [Abstract][Full Text] [Related]
8. Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Kang S; Yin J Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):653-659. PubMed ID: 38506058 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. Yoo M; Nelson RE; Cutshall Z; Dougherty M; Kohli M JCO Oncol Pract; 2023 Mar; 19(3):e449-e456. PubMed ID: 36599117 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma. Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521 [No Abstract] [Full Text] [Related]
11. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. Shay R; Nicklawsky A; Gao D; Lam ET Clin Genitourin Cancer; 2021 Aug; 19(4):370-370.e7. PubMed ID: 33674224 [TBL] [Abstract][Full Text] [Related]
12. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Fleeman N; Houten R; Nevitt S; Mahon J; Beale S; Boland A; Greenhalgh J; Edwards K; Maden M; Bhattacharyya D; Chaplin M; McEntee J; Chow S; Waddell T Health Technol Assess; 2024 Aug; 28(49):1-190. PubMed ID: 39252678 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S. Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790 [TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084 [TBL] [Abstract][Full Text] [Related]
15. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113 [TBL] [Abstract][Full Text] [Related]
17. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective. Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452 [TBL] [Abstract][Full Text] [Related]
19. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758 [TBL] [Abstract][Full Text] [Related]
20. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. Wu B; Shi L JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]